Description: Osicent (Osimertinib) is the 1st and only drug of its kind approved by USFDA for the treatment of epidermal growth factor receptor (EGFR) positive Non- Small Cell Lung Cancer (NSCLC) patient with T790M mutation.

Therapeutic indications: Osicent  is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

Product Name        :  Osicent

Generic Name        : Osimertinib
Formulation         : Tablet

Available Pack size : 30’s

Strengths           :  80mg

Website :c Osicent